Doisy College of Health Sciences, Saint Louis University, 1 N Grand Blvd, St. Louis, MO 63103, USA.
Stanford Cardiovascular Institute, School of Medicine, Stanford University, 1701 PageMill Road, Palo Alto, CA 94304, USA.
Cells. 2021 Nov 10;10(11):3112. doi: 10.3390/cells10113112.
Personalized regenerative medicine and biomedical research have been galvanized and revolutionized by human pluripotent stem cells in combination with recent advances in genomics, artificial intelligence, and genome engineering. More recently, we have witnessed the unprecedented breakthrough life-saving translation of mRNA-based vaccines for COVID-19 to contain the global pandemic and the investment in billions of US dollars in space exploration projects and the blooming space-tourism industry fueled by the latest reusable space vessels. Now, it is time to examine where the translation of pluripotent stem cell research stands currently, which has been touted for more than the last two decades to cure and treat millions of patients with severe debilitating degenerative diseases and tissue injuries. This review attempts to highlight the accomplishments of pluripotent stem cell research together with cutting-edge genomics and genome editing tools and, also, the promises that have still not been transformed into clinical applications, with cardiovascular research as a case example. This review also brings to our attention the scientific and socioeconomic challenges that need to be effectively addressed to see the full potential of pluripotent stem cells at the clinical bedside.
个体化再生医学和生物医学研究因人类多能干细胞与基因组学、人工智能和基因组编辑技术的最新进展相结合而得到激发和变革。最近，我们见证了基于 mRNA 的 COVID-19 疫苗在控制全球大流行方面的前所未有的突破性生命拯救转化，以及数十亿美元的太空探索项目的投资和最新可重复使用太空飞行器推动的太空旅游产业的蓬勃发展。现在，是时候审视多能干细胞研究的转化现状了，多能干细胞研究在过去二十多年来一直被吹捧为治愈和治疗数百万名患有严重衰弱退行性疾病和组织损伤的患者。本文综述尝试强调多能干细胞研究与前沿基因组学和基因组编辑工具的成就，以及尚未转化为临床应用的承诺，以心血管研究为例。本文综述还提请我们注意需要有效解决的科学和社会经济挑战，以在临床床边充分发挥多能干细胞的潜力。
